{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:17:59Z","timestamp":1762917479330},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,10,10]],"date-time":"2013-10-10T00:00:00Z","timestamp":1381363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Recent clinical studies suggest that fibroblast growth factor 23 (<jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23) is important in the pathogenesis of calcium\u2013phosphate abnormalities in patients with chronic kidney disease and that increased plasma <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23 concentration is a cardiovascular risk factor in these patients. The aim of this prospective, single\u2010arm, open\u2010label clinical study was to assess the influence of 6\u2010month cinacalcet treatment on plasma <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23 concentration in haemodialysed patients with secondary hyperparathyroidism (s<jats:styled-content style=\"fixed-case\">HPT<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Patients and Measurements<\/jats:title><jats:p>In 58 haemodialysed patients with s<jats:styled-content style=\"fixed-case\">HPT<\/jats:styled-content> (parathormone <jats:styled-content style=\"fixed-case\">PTH<\/jats:styled-content>\u00a0&gt;\u00a0300\u00a0ng\/l), serum <jats:styled-content style=\"fixed-case\">PTH<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> FGF<\/jats:styled-content>23, calcium and phosphate concentrations were assessed before the first dose of cinacalcet and after 3 and 6\u00a0months of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Serum <jats:styled-content style=\"fixed-case\">PTH<\/jats:styled-content> concentration decreased significantly after 3 and 6\u00a0months of treatment, and the mean serum calcium and phosphate concentrations remained stable during the treatment period. Plasma <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23 concentration (geometric mean with 95% confidence index) decreased after 3 and 6\u00a0months of treatment from 354 (261\u2013481)\u00a0ng\/l to 295 (204\u2013428)\u00a0ng\/l; <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7099 and to 183 (117\u2013285)\u00a0ng\/l; <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7015, respectively. <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23 concentration decreased in 52% of patients. In multivariate regression analysis, plasma <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23 concentration changes were explained by the changes in serum phosphate, but not by serum <jats:styled-content style=\"fixed-case\">PTH<\/jats:styled-content> or calcium changes or by the dose of cinacalcet.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>1. Cinacalcet treatment decreases plasma <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23 concentration in haemodialysed patients with secondary hyperparathyroidism. 2. The decrease in plasma <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23 concentration seems to be related to the decrease in serum phosphate concentration.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cen.12326","type":"journal-article","created":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T21:56:00Z","timestamp":1381528560000},"page":"607-612","source":"Crossref","is-referenced-by-count":11,"title":["Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism"],"prefix":"10.1111","volume":"80","author":[{"given":"Piotr","family":"Kuczera","sequence":"first","affiliation":[{"name":"Department of Nephrology, Endocrinology and Metabolic Diseases Medical University of Silesia Katowice Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Adamczak","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Endocrinology and Metabolic Diseases Medical University of Silesia Katowice Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Wiecek","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Endocrinology and Metabolic Diseases Medical University of Silesia Katowice Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,10,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M207872200"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.0301264"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2011.01443.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.26"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.414"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006080936"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn571"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.844506"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.02.012"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr208"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706130"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.352"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2005.00293.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09250912"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000319650"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.06.019"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986707782794096"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.5414\/CNP74198"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01040308"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.08.012"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03630509"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr384"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-011-0050-7"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00552.2009"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq419"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0021"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.060507"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1039"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205624"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00178.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00184.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000188261"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg451"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02110310"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcen.12326","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.12326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T09:06:38Z","timestamp":1696323998000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.12326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,10]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1111\/cen.12326"],"URL":"https:\/\/doi.org\/10.1111\/cen.12326","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,10]]}}}